GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

China SXT Pharmaceuticals SXTC · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.10

+9.54%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About China SXT Pharmaceuticals

Its shares trade under the ticker SXTC. It has been listed since 4 January 2019. In the fiscal year to 31 March 2026, it reported revenue of $1.1m and a net loss of $6.2m. At that date it held total assets of $34.8m and shareholders' equity of $29.7m.

China SXT Pharmaceuticals Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-01-04. China SXT Pharmaceuticals Inc is a China-based pharmaceutical company that focuses on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
4 Jan 2019
Employees
56
Head office
178 TAIDONG ROAD NORTH, TAIZHOU
Incorporated in
D8
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

Leadership

Pay as last reported

  • Mr. Feng ZhouCo-Chief Executive Officer, Director, since 2017$50,000
  • Mr. Lim Sze BengCo-Chief Executive Officer
  • Mr. Xiaodong PanChief Financial Officer$8,333
  • Mr. Jun ZhengDirector
  • Mr. Xiaodong JiIndependent Director
  • Mr. Tong LiuIndependent Director
  • Mr. Lip Chee YongIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company operates in Pharmaceuticals industry with focus on Traditional Chinese Medicine Pieces
  • Sells products under three brand names including Suxuangtang, Hui Chun Tang, and Tong Ren Tang
  • Products are sold on a prescription basis across China

Weaknesses

  • Company employs only 56 employees according to provided data
  • Source description states 96 employees which contradicts provided data
  • Company has limited product types with only three TCMP categories

Opportunities

  • Growth potential in Traditional Chinese Medicine market in China
  • Expansion of TCM Homologous Supplements product line
  • Increased demand for prescription-based pharmaceutical products

Threats

  • Contradictory employee count between provided data and source description
  • Dependence on prescription-based sales model in China
  • Competition in Traditional Chinese Medicine industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.